Breast Cancer Res. 2007;9(4):108.

Decline in breast cancer incidence due to removal of promoter: combination estrogen plus progestin.

Erratum in

Breast Cancer Res. 2007;9(6):401.

Abstract

Combination estrogen plus progestin causes breast cancer. In light of this causal relation, the rapid decline in breast cancer incidence noted in 2003, following an earlier and slower reduction in incidence from 1999, raises important issues regarding the proportion of this decline that may be due to a reduction in the use of combination therapy by postmenopausal women. The context of these national trends is reviewed and the strong link to the use of hormone therapy is discussed, after noting that screening cannot explain any substantial component of these trends. The rapid decrease in incidence, most evident among women aged 50 to 69 years and in estrogen receptor positive tumors, that parallels the decline in combination hormone use is consistent with a promoter effect for estrogen plus progestins.

Comment on

Breast Cancer Res. 2007;9(3):R28.

PMID:: 17666116; [PubMed - indexed for MEDLINE]
PMCID: PMC2206710

Free PMC Article

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Supplemental Content

Related citations

Review Estrogen, estrogen plus progestin therapy, and risk of breast cancer. [Clin Cancer Res. 2005]
Review Estrogen, estrogen plus progestin therapy, and risk of breast cancer.
Colditz GA. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 2):909s-17s.
Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. [J Natl Cancer Inst. 2007]
Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status.
Glass AG, Lacey JV Jr, Carreon JD, Hoover RN. J Natl Cancer Inst. 2007 Aug 1; 99(15):1152-61. Epub 2007 Jul 24.
Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population. [J Clin Oncol. 2003]
Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population.
Kerlikowske K, Miglioretti DL, Ballard-Barbash R, Weaver DL, Buist DS, Barlow WE, Cutter G, Geller BM, Yankaskas B, Taplin SH, et al. J Clin Oncol. 2003 Dec 1; 21(23):4314-21.
Hormone replacement therapy and breast cancer risk in Kyushu University Hospital: supporting the Women's Health Initiative study. [J Obstet Gynaecol Res. 2004]
Hormone replacement therapy and breast cancer risk in Kyushu University Hospital: supporting the Women's Health Initiative study.
Nozaki M, Koera K, Nagata H, Nakano H. J Obstet Gynaecol Res. 2004 Aug; 30(4):297-302.
Review Postmenopausal hormone therapy and the risk of breast cancer: a contrary thought. [Menopause. 2008]
Review Postmenopausal hormone therapy and the risk of breast cancer: a contrary thought.
Speroff L. Menopause. 2008 Mar-Apr; 15(2):393-400.

See reviews... See all...

Cited by 3 PubMed Central articles

The contribution of postmenopausal hormone use cessation to the declining incidence of breast cancer. [Cancer Causes Control. 2011]
The contribution of postmenopausal hormone use cessation to the declining incidence of breast cancer.
Sprague BL, Trentham-Dietz A, Remington PL. Cancer Causes Control. 2011 Jan; 22(1):125-34. Epub 2010 Nov 16.
Mechanisms of epigenetic silencing of the Rassf1a gene during estrogen-induced breast carcinogenesis in ACI rats. [Carcinogenesis. 2010]
Mechanisms of epigenetic silencing of the Rassf1a gene during estrogen-induced breast carcinogenesis in ACI rats.
Starlard-Davenport A, Tryndyak VP, James SR, Karpf AR, Latendresse JR, Beland FA, Pogribny IP. Carcinogenesis. 2010 Mar; 31(3):376-81. Epub 2009 Dec 14.
Rates of atypical ductal hyperplasia have declined with less use of postmenopausal hormone treatment: findings from the Breast Cancer Surveillance Consortium. [Cancer Epidemiol Biomarkers Prev. 2009]
Rates of atypical ductal hyperplasia have declined with less use of postmenopausal hormone treatment: findings from the Breast Cancer Surveillance Consortium.
Menes TS, Kerlikowske K, Jaffer S, Seger D, Miglioretti DL. Cancer Epidemiol Biomarkers Prev. 2009 Nov; 18(11):2822-8.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
References for this PMC Article
Citation referenced in PubMed article. Only valid for PubMed citations that are also in PMC.
Free in PMC
Free full text articles in PMC
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Decline in breast cancer incidence due to removal of promoter: combination estro...
Decline in breast cancer incidence due to removal of promoter: combination estrogen plus progestin.
Breast Cancer Res. 2007 ;9(4):108.

PubMed
Are herbal remedies and dietary supplements safe and effective for breast cancer...
Are herbal remedies and dietary supplements safe and effective for breast cancer patients?
Breast Cancer Res. 2003 ;5(6):300-2. Epub 2003 Oct 7 .

PubMed
I love you... and heroin: care and collusion among drug-using couples.
I love you... and heroin: care and collusion among drug-using couples.
Subst Abuse Treat Prev Policy. 2006 Mar 28 ;1:7.

PubMed
Characterization of the retinal proteome during rod photoreceptor genesis.
Characterization of the retinal proteome during rod photoreceptor genesis.
BMC Res Notes. 2010 Jan 27 ;3:25.

PubMed
Gene expression profiling to characterize sediment toxicity--a pilot study using...
Gene expression profiling to characterize sediment toxicity--a pilot study using Caenorhabditis elegans whole genome microarrays.
BMC Genomics. 2009 Apr 14 ;10:160.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to:

Decline in breast cancer incidence due to removal of promoter: combination estrogen plus progestin.

Erratum in

Abstract

Comment on

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Libraries

Supplemental Content

Related citations

Cited by 3 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information